Showing 1672 results
-
Press release /Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based…
-
Press release /Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
-
Press release /Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD…
-
Story /All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.
-
Press release /Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process…
-
Story /Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.
-
Press release /Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
-
Press release /Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
-
Press release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
-
Ad hoc release /Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…